228 related articles for article (PubMed ID: 24040417)
1. DNA topoisomerases participate in fragility of the oncogene RET.
Dillon LW; Pierce LC; Lehman CE; Nikiforov YE; Wang YH
PLoS One; 2013; 8(9):e75741. PubMed ID: 24040417
[TBL] [Abstract][Full Text] [Related]
2. DNA breaks at fragile sites generate oncogenic RET/PTC rearrangements in human thyroid cells.
Gandhi M; Dillon LW; Pramanik S; Nikiforov YE; Wang YH
Oncogene; 2010 Apr; 29(15):2272-80. PubMed ID: 20101222
[TBL] [Abstract][Full Text] [Related]
3. RET rearrangements in radiation-induced papillary thyroid carcinomas: high prevalence of topoisomerase I sites at breakpoints and microhomology-mediated end joining in ELE1 and RET chimeric genes.
Klugbauer S; Pfeiffer P; Gassenhuber H; Beimfohr C; Rabes HM
Genomics; 2001 Apr; 73(2):149-60. PubMed ID: 11318605
[TBL] [Abstract][Full Text] [Related]
4. DNA fragile site breakage as a measure of chemical exposure and predictor of individual susceptibility to form oncogenic rearrangements.
Lehman CE; Dillon LW; Nikiforov YE; Wang YH
Carcinogenesis; 2017 Mar; 38(3):293-301. PubMed ID: 28069693
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of topoisomerase I prevents chromosome breakage at common fragile sites.
Arlt MF; Glover TW
DNA Repair (Amst); 2010 Jun; 9(6):678-89. PubMed ID: 20413351
[TBL] [Abstract][Full Text] [Related]
6. ATR preferentially interacts with common fragile site FRA3B and the binding requires its kinase activity in response to aphidicolin treatment.
Wan C; Kulkarni A; Wang YH
Mutat Res; 2010 Apr; 686(1-2):39-46. PubMed ID: 20060399
[TBL] [Abstract][Full Text] [Related]
7. Breakpoint characterization of the ret/PTC oncogene in human papillary thyroid carcinoma.
Smanik PA; Furminger TL; Mazzaferri EL; Jhiang SM
Hum Mol Genet; 1995 Dec; 4(12):2313-8. PubMed ID: 8634704
[TBL] [Abstract][Full Text] [Related]
8. Role of DNA secondary structures in fragile site breakage along human chromosome 10.
Dillon LW; Pierce LC; Ng MC; Wang YH
Hum Mol Genet; 2013 Apr; 22(7):1443-56. PubMed ID: 23297364
[TBL] [Abstract][Full Text] [Related]
9. Involvement of topoisomerases in replication, transcription, and packaging of the linear adenovirus genome.
Wong ML; Hsu MT
J Virol; 1990 Feb; 64(2):691-9. PubMed ID: 2153235
[TBL] [Abstract][Full Text] [Related]
10. DNA instability at chromosomal fragile sites in cancer.
Dillon LW; Burrow AA; Wang YH
Curr Genomics; 2010 Aug; 11(5):326-37. PubMed ID: 21286310
[TBL] [Abstract][Full Text] [Related]
11. Topoisomerase Inhibitors and Targeted Delivery in Cancer Therapy.
You F; Gao C
Curr Top Med Chem; 2019; 19(9):713-729. PubMed ID: 30931860
[TBL] [Abstract][Full Text] [Related]
12. Direct cloning of DNA sequences from the common fragile site region at chromosome band 3p14.2.
Rassool FV; Le Beau MM; Shen ML; Neilly ME; Espinosa R; Ong ST; Boldog F; Drabkin H; McCarroll R; McKeithan TW
Genomics; 1996 Jul; 35(1):109-17. PubMed ID: 8661111
[TBL] [Abstract][Full Text] [Related]
13. Aphidicolin-induced FRA3B breakpoints cluster in two distinct regions.
Wang L; Paradee W; Mullins C; Shridhar R; Rosati R; Wilke CM; Glover TW; Smith DI
Genomics; 1997 May; 41(3):485-8. PubMed ID: 9169152
[TBL] [Abstract][Full Text] [Related]
14. Topoisomerase I and II cleavage of adenovirus DNA in vivo: both topoisomerase activities appear to be required for adenovirus DNA replication.
Schaack J; Schedl P; Shenk T
J Virol; 1990 Jan; 64(1):78-85. PubMed ID: 2152835
[TBL] [Abstract][Full Text] [Related]
15. A 350-kb cosmid contig in 3p14.2 that crosses the t(3;8) hereditary renal cell carcinoma translocation breakpoint and 17 aphidicolin-induced FRA3B breakpoints.
Paradee W; Wilke CM; Wang L; Shridhar R; Mullins CM; Hoge A; Glover TW; Smith DI
Genomics; 1996 Jul; 35(1):87-93. PubMed ID: 8661108
[TBL] [Abstract][Full Text] [Related]
16. Impaired replication dynamics at the FRA3B common fragile site.
Palakodeti A; Lucas I; Jiang Y; Young DJ; Fernald AA; Karrison T; Le Beau MM
Hum Mol Genet; 2010 Jan; 19(1):99-110. PubMed ID: 19815620
[TBL] [Abstract][Full Text] [Related]
17. The Fanconi anemia pathway is required for the DNA replication stress response and for the regulation of common fragile site stability.
Howlett NG; Taniguchi T; Durkin SG; D'Andrea AD; Glover TW
Hum Mol Genet; 2005 Mar; 14(5):693-701. PubMed ID: 15661754
[TBL] [Abstract][Full Text] [Related]
18. Etoposide metabolites enhance DNA topoisomerase II cleavage near leukemia-associated MLL translocation breakpoints.
Lovett BD; Strumberg D; Blair IA; Pang S; Burden DA; Megonigal MD; Rappaport EF; Rebbeck TR; Osheroff N; Pommier YG; Felix CA
Biochemistry; 2001 Feb; 40(5):1159-70. PubMed ID: 11170441
[TBL] [Abstract][Full Text] [Related]
19. Cell-type-specific replication initiation programs set fragility of the FRA3B fragile site.
Letessier A; Millot GA; Koundrioukoff S; Lachagès AM; Vogt N; Hansen RS; Malfoy B; Brison O; Debatisse M
Nature; 2011 Feb; 470(7332):120-3. PubMed ID: 21258320
[TBL] [Abstract][Full Text] [Related]
20. Distribution of 11q23 breakpoints within the MLL breakpoint cluster region in de novo acute leukemia and in treatment-related acute myeloid leukemia: correlation with scaffold attachment regions and topoisomerase II consensus binding sites.
Broeker PL; Super HG; Thirman MJ; Pomykala H; Yonebayashi Y; Tanabe S; Zeleznik-Le N; Rowley JD
Blood; 1996 Mar; 87(5):1912-22. PubMed ID: 8634439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
